SystImmune Receives FDA Clearance of IND Application for Bispecific Antibody SI-B037

RegulatoryapprovedSI-B037Positive

AI Analysis

Summary

SystImmune received FDA clearance of its IND application for SI-B037, a bispecific antibody, marking the company's first IND enabled by New Approach Methodologies (NAMs).

Outcome Details

FDA cleared IND application for bispecific antibody SI-B037

Importance:6/10

Sentiment:

0.75

IND clearancebispecific antibodyNAMsregulatory milestone

Related Companies

$GBCYD $TRAX

Read the original article

Published by PR Newswire Biotech on September 22, 2026 11:00 AM

Read Original